Limonene Study in Women With Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01046929 |
Recruitment Status :
Completed
First Posted : January 12, 2010
Last Update Posted : October 27, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Dietary Supplement: limonene | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 59 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Clinical Study of Limonene in Women With a Recent Diagnosis of Early Stage Breast Cancer Electing to Undergo Excision Surgery |
Study Start Date : | August 2009 |
Actual Primary Completion Date : | March 2011 |
Actual Study Completion Date : | March 2011 |
Arm | Intervention/treatment |
---|---|
Experimental: limonene |
Dietary Supplement: limonene
oral dosing at 2 gram QD |
- breast tissue limonene level [ Time Frame: 2 - 6 weeks ]
- drug effect biomarkers in the breast tissue and serum [ Time Frame: 2 - 6 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Women who are 18 years of age or older
- Women electing to undergo excision surgery for early stage breast cancer
- A minimum of 2 weeks from enrollment to definitive surgery
- Underwent core needle biopsy for breast cancer diagnosis
- No clinical evidence of metastatic breast cancer
- ECOG performance status 0-1
- Participants must have normal organ and marrow function
- Women of child-bearing potential must agree to use adequate contraception
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Concurrent chemotherapy or radiation therapy
- Use of selective estrogen receptor modifiers or aromatase inhibitors within the past 3 months or concurrently
- History of other malignancies within the past 5 years excluding non-melanoma skin cancer and cancers confined to organs with removal as only treatment
- Participated in another clinical intervention trial within the past 3 months
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant or breast-feeding women
- Use of dietary supplement that contains large amounts of d-limonene (such as Heartburn Free with ROH10 and CoQ with d-limonene) within the past 3 months
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01046929
United States, Arizona | |
Arizona Cancer Center | |
Tucson, Arizona, United States, 85724 |
Responsible Party: | Sherry Chow, Research Professor of Medicine, University of Arizona |
ClinicalTrials.gov Identifier: | NCT01046929 |
Other Study ID Numbers: |
UAz 09-0447-04 1R21CA123033-01A2 ( U.S. NIH Grant/Contract ) |
First Posted: | January 12, 2010 Key Record Dates |
Last Update Posted: | October 27, 2017 |
Last Verified: | October 2017 |
limonene breast cancer cancer prevention |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |